Feature | March 13, 2013

First Implant Made in Pivotal Trial Evaluating Amplatzer LAA Occluder

Device designed to prevention stroke in patients with atrial fibrillation without the use of warfarin

March 13, 2013 — St. Jude Medical Inc. announced the first patient implant in a new pivotal trial evaluating the company’s Amplatzer cardiac plug (ACP) for the prevention of stroke. The Amplatzer cardiac plug clinical trial is designed to determine if the ACP device is safe and effective in preventing thrombus (blood clots) from migrating out of the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AF) who have a high risk for stroke.

The ACP trial is a prospective, randomized, multicenter clinical study with an adaptive trial design that will enroll no fewer than 400 and no more than 3,000 patients at up to 90 sites in the United States and Canada. The trial compares the safety and efficacy of the ACP device to traditional medical treatment using long-term, blood-thinning medication.

Study investigator Christian Machado, M.D., director of electrophysiology at the Providence Hospital Heart Institute, Southfield, Mich., performed the first Amplatzer cardiac plug implant in the pivotal phase of the trial. The procedure was assisted by co-investigator Thomas Forbes, M.D., a pediatric interventional cardiologist.

“Patients with untreated atrial fibrillation are four to five times more likely to have a stroke, which greatly increases their risk of disability or death. Dr. Forbes and I consider the ACP trial an important study as we look for ways to reduce this risk,” said Machado. “We are excited to contribute research that may help expand treatment options for patients.”

The Amplatzer device has been the market leader for LAA occlusion since its introduction in 2008. A self-expanding occlusion device constructed from nitinol mesh, and delivered via catheter, the ACP device is designed to completely seal the LAA at its opening, and minimize blood clots from forming in the LAA and migrating into the bloodstream.

According to the American Heart Association, an estimated 2.7 million Americans have AF and the likelihood of developing it increases with age. Defined as a quivering or irregular heartbeat (arrhythmia), AF can lead to blood clots, stroke, heart failure and other heart-related complications. AF is the most common heart rhythm abnormality in people over the age of 65. During episodes of AF, the heart contracts at rapid and irregular intervals, which can increase the likelihood of clot formation in the LAA. If a clot is released from the LAA, it can enter the blood stream and potentially travel to the brain, resulting in a stroke.

Each ACP trial study site will have specialists in electrophysiology and interventional cardiology, forming a collaboration between the two specialties. “The current standard of care for the prevention of stroke is warfarin or other oral blood-thinning medications that can be difficult for some people to tolerate, and may carry a risk of serious complications such as bleeding,” said trial investigator James Hermiller, M.D., an interventional cardiologist from St. Vincent Hospital in Indianapolis. “As physicians, we are always looking for new ways to best treat our patients. We hope the ACP trial will prove that we can reduce the risk of stroke in patients with atrial fibrillation through this minimally invasive procedure.”

“The Amplatzer cardiac plug has shown great promise in international markets, and we look forward to establishing the evidence required to make it available in the U.S.,” said Frank J. Callaghan, president of the St. Jude Medical cardiovascular and ablation technologies division. “The ACP trial is another example of significant investment by St. Jude Medical to develop landmark clinical evidence. This trial will help us understand the long-term benefits of LAA occlusion therapy for lowering the risk of stroke in atrial fibrillation patients and potentially improve their quality of life.”

The device is currently not approved for use in the United States. The ACP trial is conducted under an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).

For more information: www.sjm.com

Related Content

Sapien III, Sapien 3, PARTNER III, FDA approval, expanded indication, intermediate risk patients

The Sapien 3 valve has a skirt of fabric at its base that has significantly reduced issues of paravalvular leak, which was an issue with the first generation Sapien device. 

Feature | Heart Valve Technology| August 18, 2016 | Dave Fornell
August 18, 2016 — The U.S.
warfarin, long-term stability, atrial fibrillation, DCRI study, Sean Pokorney
News | Antiplatelet and Anticoagulation Therapies| August 16, 2016
August 16, 2016 — Warfarin prescribed to prevent strokes in...
Sponsored Content | Videos | Heart Valve Technology| August 15, 2016
The Edwards Lifesciences Intuity Elite surgical aortic valve uses a balloon expandable skirt technology taken from th
PFO closure, patent foramen ovale, AAN recommendation, American Academy of Neurology, stroke patients
News | Structural Heart Occluders| August 08, 2016
Updated recommendations from the American Academy of Neurology (AAN) states that catheter-based closure should not be...
mitraclip, mitraclip reimbursement
News | Heart Valve Technology| August 05, 2016
August 5, 2016 — The Centers for Medicare and Medicaid Services (CMS) has reassigned MitraClip transcatheter mitral v
Absorb, bioresorbable stent, FDA approval, FDA approves, FDA clears, most popular content, most popular stories, DAIC

The FDA clearance of the first bioresorbable stent, the Abbott Absorb, the first week of July has been the most popular story so far for all of 2016. It is the first fully dissolving stent approved for the U.S. market and many experts say this technology could be a paradigm shift in coronary and peripheral therapies in the coming years as the technology improves. 

Feature | August 05, 2016 | Dave Fornell
 
CoreValve Evolut R, intermediate risk patients, european approval, CE mark
Feature | Heart Valve Technology| August 04, 2016
August 4, 2016 — Medtronic announced CE (Conformité Européenne) mark market clearnace for the self-expanding, recaptu
Watchman, left atrial appendage closure, LAA occluder

An illustration of a Watchman transcatheter LAA occluder being implanted.

Feature | Left Atrial Appendage (LAA) Occluders| August 01, 2016 | Dave Fornell
Patients with atrial fibrillation (AF or Afib) are high risk for stroke due to the formation of thrombus emboli in th
Overlay Init